About this trial
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of IPF
Age 40-95
Able to read, speak, and understand English
If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.
Disqualifiers
Patients who do not meet all inclusion criteria
Pregnant females
Trial population
ILD clinic
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
The supraglottic index (SGI) quantifies laryngopharyngeal reflux (LPF) and is associated with severity of pulmonary fibrosis.
Correlation between the supraglottic index and forced vital capacity. The supraglottic index is an index derived by assigning scores for edema and erythema of five supraglottic structures (epiglottis, false cords, arytenoids, posterior commissure, piriform recess) as viewed through a fiber-optic scope. Scores range from 0-22, with higher scores indicating more severe LPR.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.